Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 1
2004 3
2006 4
2007 2
2008 8
2009 6
2010 4
2011 13
2012 8
2013 15
2014 19
2015 21
2016 25
2017 37
2018 33
2019 38
2020 53
2021 53
2022 42
2023 34
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic HER2-Negative Breast Carcinoma"
Page 1
Male breast cancer: an update.
Fox S, Speirs V, Shaaban AM. Fox S, et al. Virchows Arch. 2022 Jan;480(1):85-93. doi: 10.1007/s00428-021-03190-7. Epub 2021 Aug 30. Virchows Arch. 2022. PMID: 34458944 Review.
BRCA2 carriers have 80 times the risk of the general population. Men generally present with breast cancer at an older age compared with women. Histologically, MBC is often of grade 2, hormone receptor positive, HER2 negative, and no special type carcinoma …
BRCA2 carriers have 80 times the risk of the general population. Men generally present with breast cancer at an older age compared wi …
Updates on breast biomarkers.
Najjar S, Allison KH. Najjar S, et al. Virchows Arch. 2022 Jan;480(1):163-176. doi: 10.1007/s00428-022-03267-x. Epub 2022 Jan 14. Virchows Arch. 2022. PMID: 35029776 Review.
Recent advancements in breast cancer treatment have ushered in a new era of precision medicine. ...Ki67 has also recently emerged as a marker that can be used to identify the highest risk ER-positive and HER2-negative cancers if considering adding a cell cycl …
Recent advancements in breast cancer treatment have ushered in a new era of precision medicine. ...Ki67 has also recently emerged as …
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D. Cristofanilli M, et al. Lancet Oncol. 2016 Apr;17(4):425-439. doi: 10.1016/S1470-2045(15)00613-0. Epub 2016 Mar 3. Lancet Oncol. 2016. PMID: 26947331 Clinical Trial.
METHODS: In this multicentre, double-blind, randomised phase 3 study, women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy were stratified by sensitivity t …
METHODS: In this multicentre, double-blind, randomised phase 3 study, women aged 18 years or older with hormone-receptor-positive, HER2 …
Prognostic and predictive biomarkers in breast cancer: Past, present and future.
Nicolini A, Ferrari P, Duffy MJ. Nicolini A, et al. Semin Cancer Biol. 2018 Oct;52(Pt 1):56-73. doi: 10.1016/j.semcancer.2017.08.010. Epub 2017 Sep 4. Semin Cancer Biol. 2018. PMID: 28882552 Review.
Following a diagnosis of breast cancer, the most immediate challenges in patient management are the determination of prognosis and identification of the most appropriate adjuvant systemic therapy. ...Oncotype DX and MammaPrint, may be used for predicting outcome and aiding …
Following a diagnosis of breast cancer, the most immediate challenges in patient management are the determination of prognosis and id …
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
BACKGROUND: Oral fluoropyrimidines, such as S-1, have been shown to have a role in controlling disease progression in metastatic breast cancer. We examined adjuvant treatment with S-1 in patients with oestrogen receptor (ER)-positive and HER2-negative …
BACKGROUND: Oral fluoropyrimidines, such as S-1, have been shown to have a role in controlling disease progression in metastatic b …
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M. Turner NC, et al. N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20. N Engl J Med. 2018. PMID: 30345905 Clinical Trial.
BACKGROUND: The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanc …
BACKGROUND: The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progressio …
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Martínez-Sáez O, Chic N, Pascual T, Adamo B, Vidal M, González-Farré B, Sanfeliu E, Schettini F, Conte B, Brasó-Maristany F, Rodríguez A, Martínez D, Galván P, Rodríguez AB, Martinez A, Muñoz M, Prat A. Martínez-Sáez O, et al. Breast Cancer Res. 2020 May 13;22(1):45. doi: 10.1186/s13058-020-01284-9. Breast Cancer Res. 2020. PMID: 32404150 Free PMC article.
PURPOSE: The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay det …
PURPOSE: The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating …
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
Navarro-Yepes J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, Singareeka Raghavendra A, Wang Y, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S, Tripathy D, Keyomarsi K. Navarro-Yepes J, et al. Cancer Res. 2023 Oct 2;83(19):3264-3283. doi: 10.1158/0008-5472.CAN-23-0705. Cancer Res. 2023. PMID: 37384539 Free PMC article.
Cyclin-dependent kinases 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is standard of care for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC). However, resistance to CDK4/6is plus ET remains a clinical …
Cyclin-dependent kinases 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is standard of care for patients with hormone receptor (HR)-pos …
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon JL, André F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC; PADA-1 investigators. Berger F, et al. BMJ Open. 2022 Mar 3;12(3):e055821. doi: 10.1136/bmjopen-2021-055821. BMJ Open. 2022. PMID: 35241469 Free PMC article. Clinical Trial.
INTRODUCTION: The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer. However, most p …
INTRODUCTION: The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive …
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
O'Sullivan CC, Clarke R, Goetz MP, Robertson J. O'Sullivan CC, et al. JAMA Oncol. 2023 Sep 1;9(9):1273-1282. doi: 10.1001/jamaoncol.2023.2000. JAMA Oncol. 2023. PMID: 37382948 Review.
IMPORTANCE: Combination therapy with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i: palbociclib, ribociclib, abemaciclib) and endocrine therapy (ET) has been a major advance for the treatment of hormone receptor-positive (HR+), ERBB2 (formerly HER2)-negative ( …
IMPORTANCE: Combination therapy with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i: palbociclib, ribociclib, abemaciclib) and endocrin …
372 results